Multiple Sclerosis

Alemtuzumab improved clinical and magnetic resonance imagining outcomes in patients with relapsing-remitting multiple sclerosis across varying age groups and maintained efficacy through year 8 of follow up.

Both the FDA and the European Medicines Agency (EMA) have accepted applications to review ozanimod, an oral sphingosine 1-phosphate receptor modulator, for the treatment of relapsing forms of multiple sclerosis (MS).

Two abstracts presented at the 33rd Annual Meeting of the Consortium of Multiple Sclerosis Centers analyzed biomarkers to predict progression, disease severity, and cognitive impairment in multiple sclerosis (MS).

Arbaclofen extended-release tablets were found to be a safe treatment that reduced spasticity in patients with multiple sclerosis.

Patients with multiple sclerosis who received natalizumab therapy had lower relapse rates and reduced inflammation.

Long-term use of ozanimod may be associated with improved cognitive speed and higher rates of no evidence of disease activity among patients with relapsing multiple sclerosis (MS), according to 2 new abstracts presented at the 33rd Annual Meeting of the Consortium of Multiple Sclerosis Centers.

Patients who switched from ozanimod HCI 0.5 mg or interferon β-1a to ozanimod HCI 1.0 mg in an open-label extension study experienced sustained reduction in their annualized relapse rate. Patients who continued on with the 1.0 mg dose also experienced a sustained reduction.

Evobrutinib, an oral Bruton’s tyrosine kinase inhibitor, reduced gadolinium-enhancing lesions in patients with multiple sclerosis.

According to new research published in PNAS, researchers have determined that a molecule that helps blood clot may also play a role in multiple sclerosis (MS) relapses, in addition to discovering a new way of studying the disease in mice that more closely resembles the human form.

Adults with relapsing multiple sclerosis (MS) who are treated with ozanimod have less gray matter volume loss than patients treated with interferon, according to a post hoc analysis from the phase 3 RADIANCE Part B trial. The research was presented at the 2019 American Academy of Neurology Annual Meeting.

During an oral presentation of abstracts at the American Academy of Neurology’s 2019 Annual Meeting in Philadelphia, Pennsylvania, held May 4-10, researchers presented findings that suggest that while pregnant women with multiple sclerosis (MS) are often viewed as high-risk by their physician, pregnancy did not seem to increase the risk of adverse obstetrical outcomes for patients nor their babies.

Research has shown that females are more susceptible to developing multiple sclerosis (MS) than males, but males have worse disease progression, and studying those sex differences can help lead to new treatments, said Rhonda Voskuhl, MD, Jack H. Skirball chair of MS research, director of the MS program, and professor of neurology at the University of California, Los Angeles (UCLA).

Analyses of real-world data have broadened the understanding of multiple sclerosis (MS) and provided a snapshot into patient conditions and healthcare costs in the years leading up to and the years after an MS diagnosis, explained Bruce Pyenson, FSA, MAAA, Principal, Consulting Actuary, Milliman, Inc, during a session highlighting findings of a recent Milliman white paper at Asembia’s 15th annual Specialty Pharmacy Summit, held April 29 to May 2 in Las Vegas, Nevada.

In a study to be presented at the American Academy of Neurology’s annual meeting next week, May 4-10, 2019, in Philadelphia, Pennsylvania, researchers found that the out-of-pocket costs for neurologic medications have increased significantly over the past 12 years, particularly for those enrolled in high-deductible health plans.

Cortical lesions play a major role in the progression of multiple sclerosis (MS). A recent study looked to longitudinally characterize the development and evolution of cortical lesions in MS across the cortical width, as well as their relationship with white matter lesion accrual.

Currently, there is no universally accepted treatment standard for multiple sclerosis (MS), but 2 abstracts being presented at the American Academy of Neurology annual meeting evaluated the use and impact of highly effective therapies.

Sex differences in multiple sclerosis (MS) has been known for some time, and studying these differences benefit both sexes, explained Rhonda Voskuhl, MD, Jack H. Skirball chair of MS research, director of the MS program, and professor of neurology at the University of California, Los Angeles.

A recent retrospective study found that nearly 18% of patients diagnosed with multiple sclerosis (MS) before being referred to a medical center for treatment were actually misdiagnosed.